Isoprenaline

Overview

Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock. Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction. The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than adrenaline. Isoprenaline was granted FDA approval on 19 February 1948.

Indication

Isoprenaline is indicated to treat mild or transient episodes of heart block not requiring electric shock or pacemakers, serious episodes of heart block and Adams-Stokes attacks not caused by ventricular tachycardia or fibrillation, and bronchospasm during anesthesia. Isoprenaline is also indicated for cases of cardiac arrest until preferable treatments like electric shock and pacemakers are available. Isoprenaline is also indicated as an adjunct therapy to fluid and electrolyte replacement therapy in hypovolemic shock, septic shock, hypoperfusion, congestive heart failure, and cardiogenic shock.

Associated Conditions

Adams-Stokes attacks
Bradycardia
Bronchospasm
Cardiac Arrest
Cardiac electrical storm
Congestive Heart Failure (CHF)
Hypoperfusion
Septic Shock
Serious Heart Block
Shock, Cardiogenic
Shock, Hypovolemic
Short QT syndrome
Syncope
Torsades de Pointes
Transient Heart Block
Ventricular Arrhythmia
Beta blocker overdose
Mild Heart Block

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies	2024/10/16	NCT06643221	Early Phase 1	Recruiting	University of Arizona
Early Neurovascular Adaptations in Aging Women	2024/07/25	NCT06520982	Early Phase 1	Recruiting	University of Missouri-Columbia
Epinephrine versus Isoprenaline During Out-of-Hospital Cardiac Arrest with Non-Shockable Rhytm (EPISO)	2025/02/03	2024-516074-29-00	Phase 3	Withdrawn	Odense University Hospital
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences	2023/08/18	NCT05997732	Phase 4	Suspended	University of Alberta
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity	2022/02/02	NCT05219799	Early Phase 1	Recruiting	University of Missouri-Columbia
Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation	2017/01/26	NCT03032965	Phase 2	Completed	University of Michigan
Augmented Interoceptive Exposure Training in Anorexia Nervosa	2017/01/12	NCT03019081	Not Applicable	Active, not recruiting	Laureate Institute for Brain Research, Inc.
Decision Support for Intraoperative Low Blood Pressure	2016/04/04	NCT02726620	Not Applicable	Completed	Vanderbilt University Medical Center
Autoimmune Basis for Postural Tachycardia Syndrome	2016/03/31	NCT02725060	Not Applicable	ENROLLING_BY_INVITATION	Vanderbilt University Medical Center
POTS Adrenergic Ab (CIHR Aims #1&2)	2016/02/04	NCT02673996	N/A	Recruiting	University of Calgary

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Isoproterenol hydrochloride	KVK-Tech, Inc.	10702-364	INTRAVENOUS	0.2 mg in 1 mL	9/12/2023
Isoproterenol Hydrochloride	Nexus Pharmaceuticals Inc	14789-015	INTRAMUSCULAR, INTRAVENOUS	0.2 mg in 1 mL	3/31/2023
Isoproterenol Hydrochloride	Eugia US LLC	55150-316	INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRACARDIAC	0.2 mg in 1 mL	2/27/2024
Isoproterenol Hydrochloride	Amring Pharmaceuticals Inc.	69918-735	INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRACARDIAC	0.2 mg in 1 mL	5/28/2021
Isoproterenol Hydrochloride	Armas Pharmaceuticals Inc.	72485-113	INTRAVENOUS, SUBCUTANEOUS, INTRAMUSCULAR, INTRACARDIAC	0.2 mg in 1 mL	8/9/2021
ISOPROTERENOL HYDROCHLORIDE	Amphastar Pharmaceuticals, Inc.	0548-9502	INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRACARDIAC	0.2 mg in 1 mL	7/16/2018
Isoproterenol Hydrochloride	STI Pharma LLC	54879-039	INTRACARDIAC, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS	1 mg in 5 mL	10/4/2022
Isoproterenol Hydrochloride	Nexus Pharmaceuticals Inc	14789-011	INTRAMUSCULAR, INTRAVENOUS	0.2 mg in 1 mL	3/31/2023
Isoproterenol Hydrochloride	Amneal Pharmaceuticals LLC	70121-1604	INTRAVENOUS	0.2 mg in 1 mL	2/22/2023
ISOPROTERENOL HYDROCHLORIDE	Amphastar Pharmaceuticals, Inc.	0548-9501	INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRACARDIAC	0.2 mg in 1 mL	7/16/2018

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
ISUPREL LIQ 0.5%	sanofi canada, inc.	02017652	Liquid - Inhalation	.5 %	12/31/1954
ISOPROTERENOL HYDROCHLORIDE INJECTION USP	marcan pharmaceuticals inc	02502623	Solution - Intravenous , Intramuscular , Subcutaneous	1 MG / 5 ML	1/6/2021
ISUPREL MISTOMETER AEM 0.25%	sanofi canada, inc.	02017660	Metered-Dose Aerosol - Inhalation	0.25 %	12/31/1958
ISUPREL LIQ INH 0.5%	sterling winthrop inc.	01923870	Liquid - Inhalation	.5 %	12/31/1992
ISUPREL LIQ 0.2MG/ML	sanofi canada, inc.	02026937	Liquid - Subcutaneous , Intramuscular , Intravenous , Intracardiac	.2 MG / ML	12/31/1956
ISOPROTERENOL HCL INJ 1:5000	International Medication Systems Ltd.	00243612	Liquid - Intravenous	.2 MG / ML	12/31/1977
ISOPROTERENOL HYDROCHLORIDE INJECTION USP	Sandoz Canada, Inc.	00897639	Solution - Subcutaneous , Intravenous , Intramuscular	0.2 MG / ML	12/31/1991
ISOPROTERENOL HYDROCHLORIDE INJECTION USP	omega laboratories limited	02290049	Solution - Intramuscular , Subcutaneous , Intravenous	0.2 MG / ML	N/A
ISUPREL MISTOMETER 125MCG/AEM	sterling winthrop inc.	01928449	Metered-Dose Aerosol - Inhalation	125 MCG / ACT	12/31/1992
ISOPROTERENOL HYDROCHLORIDE INJECTION USP	marcan pharmaceuticals inc	02502615	Solution - Subcutaneous , Intramuscular , Intravenous	0.2 MG / ML	12/11/2020

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access